GlassScriptPhysician profile
Debora Dowda
NPI 1124059365
$3,433.36
in general payments reported to CMS, 2019-2025
29 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $878 · 2022: $581 · 2023: $611 · 2024: $793 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.41 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $518.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $488.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $376.94 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $218.76 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.86 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $149.96 | 2021 | |
| Amgen INC. | $143.49 | 2021-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $91.75 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $89.84 | 2021-2022 | |
| Bardy Diagnostics, INC. | $75.00 | 2022 | |
| Pfizer INC. | $74.15 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $56.13 | 2021 | |
| Exact Sciences Corporation | $50.06 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abiomed | $40.89 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.65 | 2021-2022 | |
| Mylan Specialty L.P. | $33.62 | 2023 | Yupelri |
| Inogen, INC. | $29.83 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Phathom Pharmaceuticals, INC. | $26.81 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.22 | 2023 | Xifaxan |
| Clarus Therapeutics INC. | $18.95 | 2021 | |
| Astellas Pharma US INC | $18.20 | 2023 | Veozah |
| Recor Medical INC | $17.54 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ascensia Diabetes Care US INC. | $16.31 | 2025 | |
| Shield Therapeutics INC | $15.14 | 2023 | Accrufer |
| Ironwood Pharmaceuticals, INC | $15.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.37 | 2023 | |
| Antares Pharma, INC. | $14.18 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $14.18 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Dowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.